Bank of America CEO Brian Moynihan revealed that the bank now spends more than $250 million annually covering medicines such as Ozempic, Wegovy and Zepbound for its workforce of roughly 211,000 employees.
Here’s the number that really stands out.
Four to five years ago, that spend was zero.
Now put that into perspective.
Bank of America spends more than $2 billion a year on employee healthcare. Today, GLP-1 medicines account for more than 13% of that budget.
Moynihan says it’s an investment.
Beyond weight loss, growing clinical evidence suggests GLP-1 medicines can reduce cardiovascular risk and potentially lower healthcare costs over time. The bank also pairs drug coverage with health coaching and lifestyle support to improve long-term outcomes.
And Bank of America isn’t simply absorbing the cost.
Moynihan says the company is using its scale to negotiate aggressively with drugmakers and pharmacy benefit managers, pushing for lower prices as these medicines become a much larger part of employer healthcare spending.
But this is much bigger than one bank.
According to the latest survey by the International Foundation of Employee Benefit Plans, 36% of US employers now cover GLP-1 drugs for both diabetes and obesity, and that number continues to rise.
The bigger story?
GLP-1s are no longer just changing how obesity is treated — they’re changing how employers think about healthcare spending.
What began as a breakthrough weight-loss therapy is fast becoming one of the biggest new line items in corporate healthcare budgets. As more companies bet that healthier employees today will mean lower medical costs tomorrow, corporate America is becoming one of the biggest growth drivers for the GLP-1 market.
The GLP-1 revolution has moved beyond the doctor’s office. It’s officially entered the corporate boardroom.
Also read: Novo Nordisk sues Lilly, claiming misleading ads in weight-loss drug battle
